Sun Pharma recalls 3,263 bottles of epilepsy drug in US

Image
Press Trust of India New Delhi
Last Updated : Feb 23 2015 | 7:05 PM IST
Sun Pharma is voluntarily recalling 3,263 bottles of Levetiracetam, extended release tablets, an anti epileptic drug, in the US market.
As per the information available on the USFDA website, Sun Pharma Global Fze, a US-based unit of the company, is recalling the drug for failing "dissolution specifications".
The 750 mg tablets in 60-count bottles, were manufactured by Sun Pharmaceutical Industries at Halol, it added.
The recall was initiated by the company on January 21 this year.
It has been classified as a 'Class-II recall' which FDA defined as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote".
When contacted, a Sun Pharma spokesperson declined to comment.
Shares of Sun Pharma closed at Rs 908.70 apiece, down 0.66 per cent, on the BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 23 2015 | 7:05 PM IST

Next Story